Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd (the "Company") is dated November 21, 2025. The report discloses a significant transaction involving the acquisition of Company shares by an entity affiliated with the Executive Chairman.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in beneficial ownership and does not contain financial performance data.
Material Changes
The primary material change disclosed is the acquisition of 82,018 ordinary shares of OKYO Pharma Ltd on NASDAQ by Panetta Partners Limited. Panetta Partners Limited is an entity in which Gabriele Cerrone, the Company's Executive Chairman, holds a beneficial interest. Following this transaction, Mr. Cerrone's total beneficial holding increased to 10,464,695 shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the share acquisition. The attached news announcement (Exhibit 99.1) is furnished but not deemed "filed" for liability purposes under Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total beneficial ownership percentage of Gabriele Cerrone following the acquisition of 82,018 shares.
- Confirm the relationship and structure of Panetta Partners Limited as disclosed in the attached Exhibit 99.1.
- Review the full text of the News Announcement (Exhibit 99.1) for any additional context regarding the Executive Chairman's trading activity.
- Note that this filing does not contain updated financial statements or operational metrics.